HUP0002104A2 - Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0002104A2
HUP0002104A2 HU0002104A HUP0002104A HUP0002104A2 HU P0002104 A2 HUP0002104 A2 HU P0002104A2 HU 0002104 A HU0002104 A HU 0002104A HU P0002104 A HUP0002104 A HU P0002104A HU P0002104 A2 HUP0002104 A2 HU P0002104A2
Authority
HU
Hungary
Prior art keywords
group
general formula
pyrazolo
preparation
pharmaceutical compositions
Prior art date
Application number
HU0002104A
Other languages
English (en)
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astrazeneca Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab. filed Critical Astrazeneca Ab.
Publication of HUP0002104A2 publication Critical patent/HUP0002104A2/hu
Publication of HUP0002104A3 publication Critical patent/HUP0002104A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)

Abstract

Atalálmány tárgyát az (I) általános képletű, új pirazolo[3,4-d]pirimidindion-származékok - ahol az (I) általános képletben aszubsztituensek főbb jelentései: R1 és R2 alkil- vagy alkenilcsoport;R3 -CHR4(CH2)nAr általános képletű csoport, amelyben n értéke 0, R4hidrogénatom, és Ar kinolil-, naftil-, adott esetben szubsztituáltbenzodioxolil- vagy fenilcsoport; W hidrogénatom, hidroxi-metil-,karboxi-, alkoxi-karbonil- vagy piridilcsoport; X vegyértékvonal vagyalkiléncsoport; és Y kénatom vagy etiléncsoport - és előállításukraszolgáló eljárás, immunszuppresszánsként való gyógyászatialkalmazásuk, hatóanyagként ezeket tartalmazó gyógyszerkészítmények,valamint ezek előállítása képezik. Ó
HU0002104A 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them HUP0002104A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Publications (2)

Publication Number Publication Date
HUP0002104A2 true HUP0002104A2 (hu) 2001-01-29
HUP0002104A3 HUP0002104A3 (en) 2002-03-28

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002104A HUP0002104A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (21)

Country Link
US (1) US6028074A (hu)
EP (1) EP0975636B1 (hu)
JP (1) JP2001520645A (hu)
KR (1) KR20010006350A (hu)
CN (1) CN1259951A (hu)
AT (1) ATE245648T1 (hu)
AU (1) AU733066B2 (hu)
BR (1) BR9808540A (hu)
CA (1) CA2286078A1 (hu)
DE (1) DE69816608T2 (hu)
EE (1) EE9900465A (hu)
HU (1) HUP0002104A3 (hu)
ID (1) ID22746A (hu)
IL (1) IL132153A0 (hu)
IS (1) IS5198A (hu)
NO (1) NO995006L (hu)
PL (1) PL336230A1 (hu)
SE (1) SE9701398D0 (hu)
SK (1) SK135699A3 (hu)
TR (1) TR199902538T2 (hu)
WO (1) WO1998046606A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
KR20040066788A (ko) 2001-08-31 2004-07-27 더 락커펠러 유니버시티 프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2006127918A2 (en) * 2005-05-24 2006-11-30 Ott David M Personal care and medicinal products incorporating bound organosulfur groups
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
CA2651519A1 (en) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
KR101227738B1 (ko) 2007-12-06 2013-01-29 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
ES2551133T3 (es) 2008-12-06 2015-11-16 Intra-Cellular Therapies, Inc. Compuestos de 4,5,7,8-tetrahidro-4-oxo-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de PDE1
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5813511B2 (ja) * 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20110098730A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010065151A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
MX2011009824A (es) * 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP3127427B1 (en) 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EA031334B1 (ru) 2012-06-08 2018-12-28 Гленмарк Фармасьютикалс С.А. Амиды 2-амино-4-арилтиазольных соединений и их соли
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
EP2970279B1 (en) 2013-03-15 2020-09-16 Intra-Cellular Therapies, Inc. Organic compounds
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
CN109311886B (zh) * 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
EP3509589B1 (en) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Novel uses
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500966A (ja) * 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
KR0170567B1 (ko) * 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘

Also Published As

Publication number Publication date
HUP0002104A3 (en) 2002-03-28
AU7090998A (en) 1998-11-11
ID22746A (id) 1999-12-09
EE9900465A (et) 2000-04-17
WO1998046606A1 (en) 1998-10-22
CN1259951A (zh) 2000-07-12
EP0975636B1 (en) 2003-07-23
PL336230A1 (en) 2000-06-19
JP2001520645A (ja) 2001-10-30
EP0975636A1 (en) 2000-02-02
KR20010006350A (ko) 2001-01-26
IL132153A0 (en) 2001-03-19
SK135699A3 (en) 2000-05-16
ATE245648T1 (de) 2003-08-15
US6028074A (en) 2000-02-22
NO995006D0 (no) 1999-10-14
DE69816608T2 (de) 2004-04-15
DE69816608D1 (de) 2003-08-28
SE9701398D0 (sv) 1997-04-15
BR9808540A (pt) 2000-05-23
NO995006L (no) 1999-10-14
AU733066B2 (en) 2001-05-03
IS5198A (is) 1999-09-27
TR199902538T2 (xx) 2000-02-21
CA2286078A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
HUP0002104A2 (hu) Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
HUP0300641A2 (hu) Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
SE9504661D0 (sv) New compounds
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
IL123293A (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
MY127718A (en) Dolastatin 10 derivatives.
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
HUP9903766A2 (en) Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
ATE316083T1 (de) Adamantanderivate
IS6658A (is) Ný efnasambönd
DE60108236D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
YU14196A (sh) Estri i amidi di-supstituisanog 1,4-piperidina, postupci za njihovo dobijanje i farmakološke kompozicije koje ih sadrže
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
SE9702774D0 (sv) Novel compounds
TR199800608A2 (en) Propanolamin t�revleri, bunlar�n �retim usul�.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
DE60322064D1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
SE9802574D0 (sv) Novel compounds